Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca settles Ranbaxy lawsuit

AstraZeneca has settled a lawsuit out-of-court it filed against Ranbaxy Laboratories for patent infringement of one its proton-pump inhibitor Nexium
AstraZeneca (AZ) has settled a lawsuit out-of-court it filed against Ranbaxy Laboratories for patent infringement of one its proton-pump inhibitor (PPI) Nexium.

The two companies have notified the US District Court of New Jersey of the settlement agreement, which will see AZ licence Ranbaxy to commence sales of the generic version of Nexium. Under the terms of the agreement, Ranbaxy has conceded that all six of the AZ patents contested in the litigation are valid and enforceable. It also accepts sales of the generic product would have infringed four of AZ's patents.

Neil McCrae, spokesman for AZ, explained that the agreement does not involve a financial settlement of any kind

"We as a mater of course will defend our intellectual property against what we believe to be a generic challenge," he concluded.

David Brennan, chief executive officer of AZ, said: "I believe that this agreement is the right business decision and gives increased clarity and stability to allow us to continue investing substantially in our growing pipeline of new medicines."

Ranbaxy submitted an abbreviated new drug application (NDA) to the US Food and Drug Administration (FDA) for a generic drug originally patented by AZ.

Nexium patent litigations filed by AZ against Teva/Ivax and Dr Reddy's laboratories remain outstanding.

 

Related links:
AstraZeneca settles with Teva over Nexium

 

15th April 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics